Fei Leng

1.8k total citations
61 papers, 1.4k citations indexed

About

Fei Leng is a scholar working on Molecular Biology, Materials Chemistry and Accounting. According to data from OpenAlex, Fei Leng has authored 61 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 12 papers in Materials Chemistry and 11 papers in Accounting. Recurrent topics in Fei Leng's work include Corporate Finance and Governance (9 papers), Auditing, Earnings Management, Governance (7 papers) and Nanocluster Synthesis and Applications (6 papers). Fei Leng is often cited by papers focused on Corporate Finance and Governance (9 papers), Auditing, Earnings Management, Governance (7 papers) and Nanocluster Synthesis and Applications (6 papers). Fei Leng collaborates with scholars based in China, United States and Canada. Fei Leng's co-authors include Cheng Zhi Huang, Mingxuan Gao, Zhu Wu, Chun Fang Liu, Wei Wang, Pu Zhang, Yuan Fang Li, Zhiyan Cao, Sergio Davalos and Ehsan H. Feroz and has published in prestigious journals such as Bioinformatics, Scientific Reports and American Journal of Ophthalmology.

In The Last Decade

Fei Leng

56 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fei Leng China 18 673 420 155 142 117 61 1.4k
Shaojun Chen China 18 384 0.6× 319 0.8× 198 1.3× 159 1.1× 40 0.3× 72 1.7k
Xinyi Li China 30 671 1.0× 816 1.9× 205 1.3× 68 0.5× 104 0.9× 108 2.4k
Xiaowei Xu China 26 379 0.6× 800 1.9× 139 0.9× 333 2.3× 30 0.3× 75 1.9k
Dandan Ma China 26 606 0.9× 599 1.4× 805 5.2× 81 0.6× 45 0.4× 65 2.0k
Xiaotong Yang China 22 370 0.5× 904 2.2× 981 6.3× 253 1.8× 40 0.3× 56 2.3k
Daisuke Ishikawa Japan 24 510 0.8× 561 1.3× 192 1.2× 295 2.1× 51 0.4× 97 1.9k
Xiaolian Li China 24 393 0.6× 265 0.6× 190 1.2× 47 0.3× 14 0.1× 80 1.5k
Lanfang Wang China 27 327 0.5× 503 1.2× 102 0.7× 150 1.1× 10 0.1× 95 2.3k
Hui Jin China 28 326 0.5× 1.7k 4.0× 314 2.0× 83 0.6× 62 0.5× 93 2.5k

Countries citing papers authored by Fei Leng

Since Specialization
Citations

This map shows the geographic impact of Fei Leng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Leng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Leng more than expected).

Fields of papers citing papers by Fei Leng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fei Leng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Leng. The network helps show where Fei Leng may publish in the future.

Co-authorship network of co-authors of Fei Leng

This figure shows the co-authorship network connecting the top 25 collaborators of Fei Leng. A scholar is included among the top collaborators of Fei Leng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fei Leng. Fei Leng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Leng, Fei, et al.. (2024). Real estate depreciation and cash policy for innovative firms. International Review of Financial Analysis. 95. 103452–103452. 2 indexed citations
3.
Wang, Yu, et al.. (2024). Malignant melanoma complicated with cataract and secondary glaucoma: A case report. Oncology Letters. 28(5). 520–520. 1 indexed citations
4.
Leng, Fei, et al.. (2024). Novel cortisol trajectory sub-phenotypes in sepsis. Critical Care. 28(1). 290–290. 2 indexed citations
5.
Leng, Fei, Song Mei, Xiaolin Zhou, et al.. (2023). DVsc: An Automated Framework for Efficiently Detecting Viral Infection from Single-cell Transcriptomics Data. Genomics Proteomics & Bioinformatics. 22(2).
6.
Liu, Xuanshi, Wenjian Xu, Fei Leng, et al.. (2023). NeuroCNVscore: a tissue-specific framework to prioritise the pathogenicity of CNVs in neurodevelopmental disorders. BMJ Paediatrics Open. 7(1). e001966–e001966. 3 indexed citations
7.
Hu, Man, Tianwei Liang, Fei Leng, et al.. (2022). Outcomes of Microcatheter–Assisted Trabeculotomy for Glaucoma Associated With Sturge–Weber Syndrome and Phakomatosis Pigmentovascularis. American Journal of Ophthalmology. 248. 51–59. 3 indexed citations
8.
Zhang, Chengyue, Man Hu, Yanhui Cui, et al.. (2021). Glaucoma secondary to congenital fibrovascular pupillary membrane: a single tertiary center experience. Journal of American Association for Pediatric Ophthalmology and Strabismus. 25(5). 305–307.e3. 3 indexed citations
9.
Leng, Fei & Gregory Noronha. (2018). Relative value in corporate bond sectors. Review of Quantitative Finance and Accounting. 52(3). 717–735. 1 indexed citations
10.
Yin, Jason Dean-Chen, et al.. (2016). HIV coreceptor tropism determination and mutational pattern identification. Scientific Reports. 6(1). 21280–21280. 19 indexed citations
11.
Cao, Zhiyan, Fei Leng, Ehsan H. Feroz, & Sergio Davalos. (2013). Corporate Governance and Default Risk of Firms Cited in the SEC's Accounting and Auditing Enforcement Releases. SSRN Electronic Journal. 8 indexed citations
12.
Leng, Fei, et al.. (2013). Metal–organic framework MIL-101 as a low background signal platform for label-free DNA detection. The Analyst. 139(4). 801–806. 76 indexed citations
13.
Wang, Lin, Wencheng Zhao, Fei Leng, et al.. (2011). Glucocorticoid receptors take part in the apoptotic process of human lens epithelial cells, but the glucocorticoid receptor antagonist RU486 does not rescue the cells fully. Molecular BioSystems. 7(6). 1926–1937. 6 indexed citations
14.
Leng, Fei, et al.. (2011). Minimum Maturity Rules: The Cost of Selling Bonds Before Their Time. SSRN Electronic Journal.
15.
Yu, Dandan, Chunting Wang, Shi H, et al.. (2010). Enhancement of cisplatin sensitivity in lewis lung carcinoma by liposome-mediated delivery of a survivin mutant. Journal of Experimental & Clinical Cancer Research. 29(1). 46–46. 16 indexed citations
16.
Yan, Shan, Chunting Wang, Yang Li, et al.. (2010). Inhibition of human lung adenocarcinoma growth using survivint34a by low-dose systematic administration. Journal of Biosciences. 35(2). 209–216. 6 indexed citations
17.
Yuan, Wen, Zhiyong Li, Lina Zhou, et al.. (2010). Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Science. 101(11). 2325–2332. 130 indexed citations
18.
Mu, Bo, Lantu Gou, Yuqin Yao, et al.. (2010). Polyclonal rabbit anti-murine plasmacytoma cell globulins induce myeloma cells apoptosis and inhibit tumour growth in mice. APOPTOSIS. 16(4). 370–381. 6 indexed citations
19.
Davalos, Sergio, Fei Leng, Ehsan H. Feroz, & Zhiyan Cao. (2009). Bankruptcy Classification of Firms Investigated by the US Securities and Exchange Commission: An Evolutionary Ensemble Computing Model Approach. SSRN Electronic Journal. 2 indexed citations
20.
Chen, Hui & Fei Leng. (2004). Pay-Performance Sensitivity in a Heterogeneous Managerial Labor Market. SSRN Electronic Journal. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026